These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 18609486)

  • 41. Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction.
    Harding GF; Wild JM; Robertson KA; Lawden MC; Betts TA; Barber C; Barnes PM
    Epilepsia; 2000 Nov; 41(11):1420-31. PubMed ID: 11077455
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review.
    Maguire MJ; Hemming K; Wild JM; Hutton JL; Marson AG
    Epilepsia; 2010 Dec; 51(12):2423-31. PubMed ID: 21070215
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Changes in visual field of a child treatment with vigabatrin for 2 years].
    Mrugacz M; Bakunowicz-Łazarczyk A
    Klin Oczna; 2003; 105(5):313-4. PubMed ID: 14746187
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Visual field constriction and electrophysiological changes associated with vigabatrin.
    Besch D; Kurtenbach A; Apfelstedt-Sylla E; Sadowski B; Dennig D; Asenbauer C; Zrenner E; Schiefer U
    Doc Ophthalmol; 2002 Mar; 104(2):151-70. PubMed ID: 11999623
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Epilepsy: Vigabatrin treatment and visual field loss.
    Chiron C; Dulac O
    Nat Rev Neurol; 2011 Apr; 7(4):189-90. PubMed ID: 21364521
    [No Abstract]   [Full Text] [Related]  

  • 46. Recovery of visual field constriction following discontinuation of vigabatrin.
    Krakow K; Polizzi G; Riordan-Eva P; Holder G; MacLeod WN; Fish DR
    Seizure; 2000 Jun; 9(4):287-90. PubMed ID: 10880291
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The natural history of Vigabatrin associated visual field defects in patients electing to continue their medication.
    Best JL; Acheson JF
    Eye (Lond); 2005 Jan; 19(1):41-4. PubMed ID: 15094729
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Visual field constriction in 91 Finnish children treated with vigabatrin.
    Vanhatalo S; Nousiainen I; Eriksson K; Rantala H; Vainionpää L; Mustonen K; Aärimaa T; Alen R; Aine MR; Byring R; Hirvasniemi A; Nuutila A; Walden T; Ritanen-Mohammed UM; Karttunen-Lewandowski P; Pohjola LM; Kaksonen S; Jurvelin P; Granström ML
    Epilepsia; 2002 Jul; 43(7):748-56. PubMed ID: 12102679
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Examining visual field defects in the paediatric population exposed to vigabatrin.
    Spencer EL; Harding GF
    Doc Ophthalmol; 2003 Nov; 107(3):281-7. PubMed ID: 14711160
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Modelling the topography of absolute defects in patients exposed to the anti-epileptic drug vigabatrin and in normal subjects using automated static suprathreshold perimetry of the entire 80° visual field.
    Besch D; Schiefer U; Eter N; Burth R; Elger CE; Spitznas M; Dietz K
    Graefes Arch Clin Exp Ophthalmol; 2011 Sep; 249(9):1333-43. PubMed ID: 21380539
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Patterns of peripapillary retinal nerve fiber layer thinning in vigabatrin-exposed individuals.
    Clayton LM; Devile M; Punte T; de Haan GJ; Sander JW; Acheson JF; Sisodiya SM
    Ophthalmology; 2012 Oct; 119(10):2152-60. PubMed ID: 22853973
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Understanding and interpreting vision safety issues with vigabatrin therapy.
    Plant GT; Sergott RC
    Acta Neurol Scand Suppl; 2011; (192):57-71. PubMed ID: 22061181
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ophthalmologic and neurologic findings in two children exposed to vigabatrin in utero.
    Sorri I; Herrgård E; Viinikainen K; Pääkkönen A; Heinonen S; Kälviäinen R
    Epilepsy Res; 2005 Jun; 65(1-2):117-20. PubMed ID: 15941649
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Vigabatrin-associated bilateral simple optic nerve atrophy with visual field constriction. A case report and a survey of the literature].
    Viestenz A; Viestenz A; Mardin CY
    Ophthalmologe; 2003 May; 100(5):402-5. PubMed ID: 12748807
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Are vigabatrin-associated visual field constrictions asymptomatic?
    Schmidt T; Rüther K; Schmitz B
    J Neurol; 2004 Jul; 251(7):887-8. PubMed ID: 15258797
    [No Abstract]   [Full Text] [Related]  

  • 56. Peripheral retinal dysfunction in patients taking vigabatrin.
    McDonagh J; Stephen LJ; Dolan FM; Parks S; Dutton GN; Kelly K; Keating D; Sills GJ; Brodie MJ
    Neurology; 2003 Dec; 61(12):1690-4. PubMed ID: 14694031
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Vigabatrin: balancing effectiveness vs. (irreversible) visual field loss as a side effect].
    Hardus P; Engelsman M; van Veelen CW; Stilma JS
    Ned Tijdschr Geneeskd; 2000 Oct; 144(43):2066-9. PubMed ID: 11072511
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Visual field loss in young children and mentally handicapped adolescents receiving vigabatrin.
    Werth R; Schädler G
    Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):3028-35. PubMed ID: 16799049
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings.
    Miller NR; Johnson MA; Paul SR; Girkin CA; Perry JD; Endres M; Krauss GL
    Neurology; 1999 Dec; 53(9):2082-7. PubMed ID: 10599785
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Visual field constriction in children with epilepsy on vigabatrin treatment.
    Iannetti P; Spalice A; Perla FM; Conicella E; Raucci U; Bizzarri B
    Pediatrics; 2000 Oct; 106(4):838-42. PubMed ID: 11015531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.